Artaç, MehmetBozcuk, HakanAfacan, BernaÖzdoğan, MustafaSamur, Mustafa2020-03-262020-03-2620080960-9776https://dx.doi.org/10.1016/j.breast.2008.01.007https://hdl.handle.net/20.500.12395/22926We aimed to identify whether abdominal fat distribution could affect the outcome in metastatic breast cancer (MBC) patients treated with aromatase inhibitors (AIs) or not. A total of 42 MBC patients treated with first line hormonal therapy were enrolled in this study. Factors associated with overall survival in the univariate analysis were age, c-erb-B2 expression intensity (+++ versus others by immunohistochemistry), and WHR, whereas only WHR retained significance in the multivariate analysis. Median overall survival figures were 472 days versus unreached for patients with a WHR of <0.92 and ?0.92 (Log rank statistic = 9.76, P = 0.002). Similarly, the corresponding progression free survival figures for patients with a WHR of <0.92 and ?0.92 were 423 versus 1004 days (Log rank statistic = 6.37, P = 0.012). This study suggests that WHR may serve as a potential predictive marker in MBC patients treated with AIs. © 2008 Elsevier Ltd. All rights reserved.en10.1016/j.breast.2008.01.007info:eu-repo/semantics/openAccessAromatase inhibitorsBody fat distributionHormonotherapyMetastatic breast cancerWaist-to-hip ratioArticle17441842218455405Q1WOS:000259711400017Q2